PointFit sweat patch wearable
PointFit, backed by Seveno Capital, is developing a next-generation skin patch for non-invasive, real-time biomarker monitoring via sweat [https://portal.sina.com.hk/finance/finance-prnewswire/prnasia/2026/03/09/1592250/seveno-capital-invests-in-pointfit-as-next-generation-wearable-patch-signals-a-break-from-traditional-wearable-devices/]. This promises continuous health feedback without the bulk of traditional wearables.
PointFit's $10 million valuation reflects investor confidence in next-generation wearables. The company's skin patch offers continuous lactate monitoring (CLM), a key indicator of fatigue, endurance, and recovery. This eliminates the need for invasive blood tests or lab analysis. PointFit's technology, incubated at the Hong Kong University of Science and Technology (HKUST), utilizes a proprietary nanomembrane to capture biochemical signals from sweat. The company licenses the material from HKUST and has patents for its sensor architecture. Its technology transmits data via Bluetooth to a companion iOS and Apple Watch application. The wearable skin patch market is projected to reach $20 billion by 2029. PointFit is initially targeting endurance athletes, estimating a $15 billion serviceable market. Its platform is designed to expand into broader diagnostic applications, including metabolic health and longevity-focused care. Competitors in the wearable sweat sensor market primarily focus on hydration and electrolytes, not lactate. PointFit received a CES Innovation Award in Digital Health at CES 2026. Seveno Capital's investment underscores the growing trend of continuous, real-time biological insight in health tech.
